Michelle Jones is a European and Chartered (UK) Patent Attorney. Michelle joined Astex in 2000.
Handling a global portfolio of preclinical, clinical and marketed pharmaceutical compounds, Michelle is experienced in a wide range of areas including European, US and foreign patent practice, as well as freedom-to-operate and IP license strategies. She has extensive experience of IP due diligence activities to support collaboration and licensing initiatives, external fund-raising and investment decisions as well as involvement in research collaboration agreement negotiations.
She is Vice-Chair of the BioIndustry Association IP Advisory Committee, member of the CIPA Life Science Committee and Fellow of the Royal Society of Chemistry. Michelle obtained a B.Sc.(Hons) from University of Birmingham and Ph.D. from University of Cambridge.
Michelle has been recognised in the 2019 edition of IAM Strategy 300: The World’s Leading IP Strategists, an annual list of individuals who lead the way in the development and implementation of world-class IP value creation programmes.